Mitomycin

CHEMBL105 Phase 4 承認済み Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
334.3 g/mol
LogP
-0.4
Phase
4

This chemotherapy drug acts like a prodrug that becomes activated inside cells to cross-link DNA strands, preventing cancer cells from dividing. It is used to treat bladder, breast, and other cancers, and can be applied directly into the bladder for bladder cancer treatment.

分子量

334.3300 g/mol

LogP

-0.40

TPSA

147.00 Ų

リピンスキーの五則

適合

治療領域

作用機序

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

機序

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

2D構造

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CO[C@@]12[C@H](COC(N)=O)C3=C(C(=O)C(C)=C(N)C3=O)N1C[C@@H]1N[C@@H]12

InChI

InChI=1S/C15H18N4O5/c1-5-9(16)12(21)8-6(4-24-14(17)22)15(23-2)13-7(18-13)3-19(15)10(8)11(5)20/h6-7,13,18H,3-4,16H2,1-2H3,(H2,17,22)/t6-,7+,13+,15-/m1/s1

Molecular Formula

C15H18N4O5

HBD / HBA

3 / 8

回転可能結合数

4

重原子数

24

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

This chemotherapy drug acts like a prodrug that becomes activated inside cells to cross-link DNA strands, preventing cancer cells from dividing. It is used to treat bladder, breast, and other cancers, and can be applied directly into the bladder for bladder cancer treatment.

Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.

Yes, Mitomycin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL105. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 5746. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-28.

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.